An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Cemiplimab (Primary)
- Indications Cervical cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 29 Sep 2017 Status changed from not yet recruiting to recruiting.
- 17 Aug 2017 Status changed from planning to not yet recruiting.
- 10 Aug 2017 New trial record